



ALABAMA MEDICAID AGENCY

PREFERRED DRUG LIST (PDL) REFERENCE TOOL

Table of Contents

<u>Antigout Agents</u>	Page 2
<u>Antihistamine</u>	Page 2
<u>Anti-infective Agents</u>	Page 2
<u>Behavioral Health</u>	Page 6
<u>Cardiovascular Health</u>	Page 9
<u>Diabetic Agents</u>	Page 14
<u>Disease-Modifying Antirheumatic Drugs/TIMs</u>	Page 16
<u>Eye, Ear, Nose, and Throat (EENT) Preparations</u>	Page 17
<u>Gastrointestinal Agents</u>	Page 18
<u>Genitourinary Agents</u>	Page 19
<u>Hormones and Synthetic Substitutes</u>	Page 19
<u>Hereditary Angioedema Agents</u>	Page 19
<u>Immunomodulatory Agents used to treat MS</u>	Page 20
<u>Pain Management & Autonomic Agents</u>	Page 20
<u>Allergy and Respiratory Agents</u>	Page 22
<u>Skin & Mucous Membrane Agents</u>	Page 23
<u>Women's Health</u>	Page 26

Note: This PDL reference tool is to aid a prescriber with generic availability and preferred product status.

Note: A "substitution allowed" prescriber signature on a prescription should not require a PA to be obtained if a generic agent is available, if applicable.

Footnotes:

*Denotes a generic available in at least one dosage form or strength (generic will be on corresponding line where applicable)

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place. This may include a point-of-sale edit, electronic PA, or a PA form submission, as needed, depending on the specific class/agent. Please see additional information in the External Criteria on the Medicaid website.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/ Biologics/ DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		NO PA REQUIRED	PA REQUIRED
Preferred Brand		Preferred Generic	Non-Preferred Brand or PA Generic
Antigout Agents			
Antigout Agents			
none	allopurinol	Aloprim*	
	colchicine tablets	Colcrys*	
		colchicine capsules	
		Gloperba	
		Krystexxa	
		Mitigare*	
	febuxostat	Uloric*	
	probenecid		
	probenecid-colchicine		
Antihistamines			
First Generation Antihistamines			
none		Ryclora	
	clemastine (tablet)	Clemastine (generic syrup)	
	diphenhydramine		
Anti-Infective Agents			
Adamantanes			
none	amantadine	none	
	rimantadine		
Amebicides			
none	paromomycin	none	
Aminoglycosides			
Bethkis*		tobramycin inhalation solution (generic Bethkis)	
Kitabis*		tobramycin inhalation solution (generic Kitabis)	
		Arikayce	
	tobramycin inhalation solution (generic TOBI)	TOBI*	
		TOBI Podhaler	
		Zemdri	
	amikacin		
	gentamicin		
	neomycin		
	streptomycin		
	tobramycin		
Anthelmintics			
none	praziquantel	Biltricide*	
		Egaten	
		Emverm	
	ivermectin	Stromectol*	
	albendazole		
Antifungals			
none		Abelcet	
	amphotericin B liposome	AmBisome*	
	flucytosine	Ancobon*	
		Brexafemme	
	caspofungin	Cancidas*	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Cresemba
	fluconazole	Diflucan*
		Eraxis
	micafungin	Mycamine*
	posaconazole	Noxafil*
		Rezzayo
	itraconazole	Sporanox*
		Tolsura
	voriconazole	Vfend*
		Vivjoa
	amphotericin B	
	griseofulvin	
	ketoconazole	
	nystatin	
	terbinafine	
Antileprosy Agents		
none	dapsone	none
Antimalarials		
none		Coartem
		Krintafel
	atovaquone and proguanil	Malarone*
		Sovuna
	chloroquine	
	hydroxychloroquine	
	mefloquine	
	primaquine	
	pyrimethamine	
	quinine	
Antiprotozoals, Cryptosporidiosis		
none	nitazoxanide	none
Antiprotozoals, Miscellaneous		
		Impavido**
none	none	Lampit
Antiprotozoals, Nitroimidazole-derivative		
none		Likmez
		Solosec
	benznidazole	
	metronidazole	
	tinidazole	
Antiprotozoals, <i>Pneumocystis jirovecii</i> Pneumonia		
none	atovaquone	Mepron*
	pentamidine	NebuPent*
	pentamidine	Pentam 300*
Antituberculosis Agents		
none	ethambutol	
	rifabutin	Mycobutin*
	rifapentine	Priftin*
	rifampin	Rifadin*
		Sirturo
		Trecator

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	cycloserine	
	isoniazid	
	pretomanid	
	pyrazinamide	
Cephalosporins		
none		Avycaz
	cefotaxime	Claforan*
		Fetroja
	ceftazidime	Tazicef*
		Teflaro
		Zerbaxa
	cefaclor	
	cefadroxil	
	cefazolin	
	cefdinir	
	cefepime	
	cefixime	
	cefpodoxime	
	cefprozil	
	ceftriaxone	
	cefuroxime	
	cephalexin	
Chloramphenicol		
none	chloramphenicol	none
CMV Antivirals		
none	none	Livtency
		Prevymis
Coronavirus (COVID-19)		
Paxlovid	none	none
Endonuclease Inhibitors †The preferred status of this product is contingent upon statewide influenza epidemiology status as reported by the CDC		
Xofluza†	none	none
HCV Antivirals		
Mavyret ^{CC}		
Zepatier ^{CC}		
	sofosbuvir-velpatasvir ^{CC}	Epclusa*
	ledipasvir-sofosbuvir ^{CC}	Harvoni*
		Sovaldi
		Vosevi
HDV Antivirals		
		Hepcludex**
Interferons		
none	none	Pegasys
Macrolides		
none		Difcid
	erythromycin ethylsuccinate	E.E.S.*
	erythromycin ethylsuccinate	EryPed*
	erythromycin lactobionate	Erythrocine Lactobionate*
		Erythrocine Stearate
	azithromycin	Zithromax*

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	clarithromycin	
	clarithromycin ER	
	erythromycin base	
Miscellaneous Antibacterials		
none		Aemcolo DR
	clindamycin	Cleocin*
	colistimethate	Coly-Mycin M*
		Dalvance
	vancomycin	Firvanq*
		Kimyrsa
	lincomycin	Lincocin*
		Nuzolvence**
		Orbactiv
	bismuth/metronid/tetracycline	Pylera*
		Sivextro
	vancomycin	Vancocin*
		Vibativ
		Xenleta
		Xifaxan
	linezolid	Zyvox*
	daptomycin	
	polymyxin B sulfate	
Miscellaneous Antivirals		
none	foscarnet	Foscavir*
Miscellaneous β-Lactams		
none	aztreonam	Azactam*
		Cayston
	cefotetan	Cefotan*
	imipenem and cilastatin	Primaxin*
		Recarbrio
		Vabomere
	ertapenem	
	cefoxitin	
	meropenem	
Neuraminidase Inhibitors		
†The preferred status of this product is contingent upon statewide influenza epidemiology status as reported by the CDC		
Relenza†		
		Rapivab
	oseltamivir†	Tamiflu*
Nucleosides and Nucleotides		
(Note: Viread is a non-PDL agent available with no PA for hep B treatment)		
none	entecavir	Baraclude*
	adefovir	
	valganciclovir	Valcyte*
	valacyclovir	Valtrex*
		Veklury
		Vemlidy
	ribavirin	
	acyclovir	
	cidofovir	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		NO PA REQUIRED	PA REQUIRED
Preferred Brand		Preferred Generic	Non-Preferred Brand or PA Generic
	famciclovir		
	ganciclovir		
Penicillins			
none	amoxicillin and clavulanate		Augmentin*
			Bicillin C-R
			Bicillin L-A
	penicillin G		Pfizerpen*
	ampicillin and sulbactam		Unasyn*
	piperacillin and tazobactam		Zosyn*
	amoxicillin		
	ampicillin		
	dicloxacillin		
	nafcillin		
	oxacillin		
	penicillin VK		
Quinolones			
none			Baxdela
	ciprofloxacin		Cipro*
	ciprofloxacin ER		
	levofloxacin		
	moxifloxacin		
	ofloxacin		
Sulfonamides			
none	sulfasalazine		Azulfidine*
	sulfamethoxazole and trimethoprim		Bactrim*
	sulfamethoxazole and trimethoprim		Bactrim DS*
	sulfadiazine		
Tetracyclines			
none	doxycycline		Doryx*
			Minocin
	doxycycline		Morgidox*
			Nuzyra
	tigecycline		Tygacil*
			Xerava
	demeclocycline		
	minocycline		
	tetracycline		
Urinary Anti-infectives			
none	nitrofurantoin and nitrofurantoin macrocrystals		Macrobid*
	methenamine, methylene blue, phenyl salicylate, sodium phosphate, and hyoscyamine		Uribel*
			Urelle
	fosfomycin		
	nitrofurantoin macrocrystals		
	methenamine		
	methenamine, sodium phosphate, methylene blue and hyoscyamine		
	trimethoprim		
Behavioral Health			
Alzheimer's Agents			

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
none		Adlarity
	donepezil	Aricept*
	rivastigmine	Exelon*
		Kisunla
		Legembi
		Legembi Iqlik
	memantine	Namenda*
	memantine	Namenda XR*
	memantine and donepezil	Namzaric*
		Zunveyi DR
	galantamine	
Antidepressants		
none	clomipramine	Anafranil*
		Aplenzin
		Auvelity ER
	citalopram	Celexa*
	duloxetine	Cymbalta*
		desvenlafaxine ER (generic Khedezla)
		Drizalma
	venlafaxine	Effexor XR*
		Emsam
		Fetzima
	bupropion	Forfivo XL*
	escitalopram	Lexapro*
		Marplan
	phenelzine	Nardil*
	desipramine	Norpramin*
	nortriptyline	Pamelor*
	paroxetine	Paxil*
	paroxetine	Paxil CR*
		Pexeva
	desvenlafaxine succinate	Pristiq*
	fluoxetine	Prozac*
		Raldesy
	mirtazapine	Remeron*
		sertraline capsules (generic)
	doxepin	Silenor*
		Spravato
		Trintellix
	vilazodone	Viibryd*
	bupropion	Wellbutrin SR*
	bupropion	Wellbutrin XL*
	sertraline	Zoloft*
		Zuruvae
	amitriptyline	
	amitriptyline and chlorthalidone	
	amoxapine	
	fluvoxamine	
	imipramine	
	maprotiline	
	nefazodone	
	protriptyline	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	tranylcypromine	
	trazodone	
	trimipramine	
Anxiolytics, Sedatives, and Hypnotics: Barbiturates		
none		Amytal Sodium
		Sezaby
	pentobarbital	
	phenobarbital	
Anxiolytics, Sedatives, and Hypnotics: Benzodiazepines		
none	diazepam rectal kit	
		Alprazolam Intensol
	lorazepam	Ativan*
	triazolam	Halcion*
	clonazepam	Klonopin*
		Loreev XR
	temazepam	Restoril*
	clorazepate	Tranxene*
	alprazolam	Xanax*
	alprazolam ER	Xanax XR*
	chlordiazepoxide	
	diazepam	
	estazolam	
	flurazepam	
	midazolam	
	oxazepam	
Anxiolytics, Sedatives, and Hypnotics: Miscellaneous Agents		
none	zolpidem	Ambien*
	zolpidem	Ambien CR*
		Edluar
	tasimelteon	Hetlioz*
	eszopiclone	Lunesta*
	dexmedetomidine	Precedex*
	ramelteon	Rozerem*
	hydroxyzine	Vistaril*
	buspirone	
	droperidol	
	meprobamate	
	zaleplon	
Cerebral Stimulants/ Agents Used for ADHD (Short- and Intermediate-Acting)		
Ritalin*	methylphenidate	
	amphetamine-dextroamphetamine	Adderall*
	amphetamine	Evekeo*
	dexmethylphenidate IR	Focalin*
	methylphenidate	Methylin*
	dextroamphetamine	ProCentra*
	dextroamphetamine	Zenzedi*
	methamphetamine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Cerebral Stimulants/ Agents Used for ADHD (Long-Acting)		
Adderall XR*	amphetamine-dextroamphetamine ER	
Concerta*	methylphenidate ER	
Focalin XR*	dexmethylphenidate ER	
Vyvanse Capsules*	lisdexamfetamine dimesylate	
		Adzenys XR-ODT
	methylphenidate	Aptensio XR*
		Azstarys
		Cotempla XR
	dextroamphetamine	Dexedrine*
		Dyanavel XR
	guanfacine ER	Intuniv*
		Jornay PM
	dextroamphetamine-amphetamine ER	Mydayis ER*
		Qelbree ER
		Quillichew ER
		Quillivant XR
	methylphenidate	Relexxi ER*
	methylphenidate	Ritalin LA*
	methylphenidate transdermal patch	
	atomoxetine	Strattera*
	lisdexamfetamine dimesylate (generic chewable)	Vyvanse Chewable Tablets*
		Xelstrym
	clonidine ER	
Orexin Receptor Antagonists		
none	none	Belsomra
		Dayvigo
		Quviviq
Wakefulness Promoting Agents		
none	armodafinil	Nuvigil*
	modafinil	Provigil*
		Sunosi
		Wakix
		Xyrem
		Xywav
Cardiovascular Health		
ACE Inhibitors		
none	quinapril	Accupril*
	quinapril and HCTZ	Accuretic*
	enalapril	Epaned*
	benazepril	Lotensin*
	benazepril and HCTZ	Lotensin HCT*
		Qbrelis
	lisinopril and HCTZ	Zestoretic*
	lisinopril	Zestril*
	captopril	
	captopril and HCTZ	
	enalapril and HCTZ	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	fosinopril	
	fosinopril and HCTZ	
	moexipril	
	perindopril	
	ramipril	
	trandolapril	
	trandolapril and verapamil	
Alpha-Adrenergic Blocking Agents		
none	doxazosin	Cardura*
		Cardura XL
		Tezruly
	prazosin	
	terazosin	
Angiotensin II Receptor Antagonists		
none		Arbli
	candesartan	Atacand*
	candesartan and HCTZ	Atacand HCT*
	irbesartan and HCTZ	Avalide*
	irbesartan	Avapro*
	olmesartan	Benicar*
	olmesartan and HCTZ	Benicar HCT*
	losartan	Cozaar*
	valsartan	Diovan*
	valsartan and HCTZ	Diovan HCT*
		Edarbi
		Edarbyclor
	losartan and HCTZ	Hyzaar*
	telmisartan	Micardis*
	telmisartan and HCTZ	Micardis HCT*
	olmesartan, amlodipine, and HCTZ	Tribenzor*
	telmisartan and amlodipine	
Angiotensin II Receptor Antagonists/Neprilysin Inhibitors		
none	sacubitril and valsartan	Entresto*
Antiarrhythmic Agents		
none		Multaq
	disopyramide	Norpace*
		Norpace CR
	amiodarone	Pacerone*
	dofetilide	Tikosyn*
	flecainide	
	mexiletine	
	propafenone	
	quinidine	
Oral Anticoagulants		
Eliquis		
Pradaxa (pellets)		
Xarelto*	rivaroxaban	
	warfarin	
	dabigatran	Pradaxa* (capsule)
		Savaysa
Beta-Adrenergic Blocking Agents		

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Hemangeol ^{CC}		
	sotalol	Betapace*
	sotalol	Betapace AF*
	nebivolol	Bystolic*
	propranolol	Inderal LA*
		Inderal XL
		InnoPran XL
		Kapspargo
	metoprolol	Lopressor*
		Sotylize
	atenolol and chlorthalidone	Tenoretic*
	atenolol	Tenormin*
	metoprolol	Toprol XL*
	acebutolol	
	betaxolol	
	bisoprolol	
	bisoprolol and HCTZ	
	carvedilol	
	labetalol	
	metoprolol and HCTZ	
	nadolol	
	nadolol and bendroflumethiazide	
	pindolol	
	timolol	
Calcium-Channel Blocking Agents		
none	amlodipine and olmesartan	Azor*
	diltiazem	Cardizem*
	diltiazem	Cardizem CD*
	diltiazem	Cardizem LA*
	amlodipine and valsartan	Exforge*
	amlodipine, valsartan and HCTZ	Exforge HCT*
		Katerzia
	amlodipine and benazepril	Lotrel*
	diltiazem	Matzim LA*
		Norliqva
	amlodipine	Norvasc*
		Nymalize
	nifedipine	Procardia XL*
	nisoldipine	Sular ER*
	diltiazem	Tiazac*
	verapamil	Verelan PM*
	felodipine	
	isradipine	
	nicardipine	
	nimodipine	
	nisoldipine	
Cardiotonic Agents		
none	ivabradine	Corlanor*
	digoxin	Lanoxin*
		Lanoxin Pediatric
Central Alpha-Agonists		
none		Nexiclon XR

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	clonidine patches	
	clonidine	
	guanfacine	
	methyldopa	
cGMP Synthesis Agents		
none	none	Verquvo
Direct Vasodilators		
none	isosorbide dinitrate-hydralazine	BiDil*
	hydralazine	
	minoxidil	
Endothelin Receptor Antagonists		
none	none	Tryvio
Diuretics		
none		Furoscix
		Hemiclor
	furosemide	Lasix*
		Thalitone
	amiloride	
	amiloride and HCTZ	
	bumetanide	
	ethacrynic acid	
	chlorthalidone	
	chlorothiazide	
	hydrochlorothiazide (HCTZ)	
	indapamide	
	metolazone	
	torsemide	
	triamterene	
	triamterene and HCTZ	
Mineralocorticoid (Aldosterone) Receptor Antagonists		
none	spironolactone	Aldactone*
	spironolactone	Carospir*
	eplerenone	Inspira*
		Kerendia
	spironolactone and HCTZ	
Miscellaneous Cardiac Drugs		
none		Aspruzo
		Attruby
		Camzyos
		Vyndamax
		Vyndagel
	ranolazine	
Nitrates and Nitrites		
Nitro-Bid*	nitroglycerin	
Nitrostat*	nitroglycerin	
		GoNitro
	isosorbide dinitrate	Isordil*
	nitroglycerin	Nitro-Dur*
	nitroglycerin	Nitrolingual*
	isosorbide mononitrate	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Nonsteroidal Anti-inflammatory Cardiovascular Drugs		
none	none	Lodoco
Platelet-aggregation Inhibitors		
none	ticagrelor	Brilinta*
	prasugrel	Effient*
	clopidogrel	Plavix*
	aspirin and dipyridamole	
	cilostazol	
	dipyridamole	
Renin Inhibitors		
none	aliskiren	Tektura*
Sodium-glucose (SGLT) Cotransporter Inhibitors		
none	none	Inpefa
Vasopressin Antagonists		
none	tolvaptan	Jynarque*
	tolvaptan	Samsca*
ACL Inhibitors		
none	none	Nexletol
		Nexlizet
ANGPTL3 Inhibitors		
none	none	Evkeeza
Bile Acid Sequestrants		
none	colestipol	Colestid*
	cholestyramine	Questran*
	cholestyramine	Questran Light*
	colesevelam	Welchol*
Cholesterol Absorption Inhibitors		
none	ezetimibe	Zetia*
Fibric Acid Derivatives		
none	fenofibrate	Lipofen*
	gemfibrozil	Lopid*
	fenofibrate, nanocrystallized	TriCor*
	fenofibric acid	Trilipix*
	fenofibrate, micronized	
HMG-CoA Reductase Inhibitors		
none		Altoprev
		Atorvaliq
	amlodipine/atorvastatin	Caduet*
		Ezallor
		Flolipid
	fluvastatin	Lescol XL*
	atorvastatin	Lipitor*
	pitavastatin	Livalo*
	simvastatin/ezetimibe	Vytorin*
	simvastatin	Zocor*
		Zypitamag
	lovastatin	
	pravastatin	
	rosuvastatin	
Miscellaneous Antilipemic Agents		

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
none		Leqvio
		Tryngolza
	niacin	
Microsomal Triglyceride Transfer Protein (MTP) Inhibitors		
none	none	Juxtapid
Omega-3-mediated Antilipemics		
none	icosapent ethyl	none
	omega-3 acid ethyl esters	
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors		
none	none	Praluent
		Repatha
Diabetic Agents		
Alpha-Glucosidase Inhibitors		
none	acarbose	none
	miglitol	
Amylinomimetics		
none	none	SymlinPen
Antidiabetic Agents, Miscellaneous		
none	mifepristone	Korlym*
		Tzield
Biguanides		
none		Glumetza*
		metformin ER (generic Glumetza ER)
	metformin	
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors		
Janumet		
Janumet XR		
Januvia		
Jentadueto		
Jentadueto XR		
Kazano*		alogliptin-metformin (generic)
Oseni*		alogliptin-pioglitazone (generic)
Tradjenta		
	alogliptin	Nesina*
	sitagliptin	Zituvio*
	saxagliptin	
	saxagliptin-metformin	Zituvimet*
	saxagliptin-metformin XR	Zituvimet XR*
Incretin Mimetics		
^Zepbound is preferred with clinical criteria for its Obstructive Sleep Apnea (OSA) with obesity indication. Zepbound is non-covered for weight reduction without OSA. #Wegovy is available via PA for its cardiovascular and metabolic dysfunction-associated steatohepatitis (MASH) indications. Wegovy is non-covered for weight reduction.		
Byetta ^{cc}		exenatide (generic)
Mounjaro ^{cc}		
Ozempic ^{cc}		

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Rybelsus ^{cc}		
Trulicity ^{cc}		
Victoza ^{*cc}		liraglutide (generic)
Zepbound ^{cc ^}		
		Wegovy [#]
Meglitinides		
none	nateglinide	none
	repaglinide	
Insulins		
Humalog*	insulin lispro	
Humalog Mix		
Humulin R (U-500)		
Lantus*		insulin glargine
Novolog Mix		
		Admelog
		Afrezza
		Apidra
		Apidra Solostar
		Awqli
		Basaglar
		Fiasp
		Kirsty
		Levemir
		Lyumjev
		Merilog
		Myxredlin
	insulin aspart	Novolog*
		Rezvoglar
		Semglee
		Soliqua
		Tresiba
		Toujeo Max Solostar*
		insulin glargine max solostar (generic)
		Toujeo Solostar*
		insulin glargine solostar (generic)
		Xultophy
	Humulin N	
	Humulin R	
	Humulin 70/30	
	insulin lispro protamine 72/25 mix pen	
	Novolin N	
	Novolin R	
	Novolin 70/30	
Sodium-glucose Co-transporter 2 Inhibitors		
Jardiance		
Synjardy		
Synjardy XR		
Xigduo XR*		dapagliflozin/metformin ER (generic)
	dapagliflozin	Farxiga*
		Glyxambi
		Invokamet

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Invokamet XR
		Invokana
		Qtern
		Segluromet
		Steglatro
		Steglujan
		Trijardy XR
Sulfonylureas		
none	glimepiride	
	glipizide	Glucotrol XL*
	glyburide	
	glipizide and metformin	
	glyburide and metformin	
Thiazolidinediones		
none	pioglitazone and metformin	Actoplus Met*
	pioglitazone	Actos*
	pioglitazone and glimepiride	Duetact*
Disease-Modifying Antirheumatic Agents		
Therapeutics Immunomodulators (TIMs)/ Disease-Modifying Antirheumatic Agents (DMARDs)		
Enbrel ^{CC,TIM}		
Humira ^{CC,TIM}		
Otezla ^{CC,TIM}		
Rinvog ^{CC,TIM}		
Starjemza ^{CC,TIM}		
Yesintek ^{CC,TIM}		
		Abrilada ^{TIM}
		Actemra ^{TIM}
		Amjevita ^{TIM}
	leflunomide ^{TIM}	Arava* ^{TIM}
		Avsola ^{TIM}
		Benlysta ^{TIM}
		Cimzia ^{TIM}
		Cosentyx ^{TIM}
		Cyltezo ^{TIM}
		Entyvio ^{TIM}
		Hadlima ^{TIM}
		Hulio ^{TIM}
		Hyrimoz ^{TIM}
		Inflectra ^{TIM}
		Kevzara ^{TIM}
		Kineret ^{TIM}
		Lupkynis ^{TIM}
		Olumiant ^{TIM}
		Orencia ^{TIM}
	infliximab ^{TIM}	Remicade* ^{TIM}
		Renflexis ^{TIM}
		Saphnelo ^{TIM}
		Simlandi ^{TIM}
		Simponi ^{TIM}

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Simponi Aria ^{TIM}
		Stelara ^{TIM}
		Taltz ^{TIM}
		Tofidence ^{TIM}
		Tyenne ^{TIM}
		Xeljanz ^{TIM}
		Xeljanz XR ^{TIM}
		Yuflyma ^{TIM}
		Yusimry ^{TIM}
		Zymfentra ^{TIM}
Eye, Ear, Nose, and Throat (EENT) Preparations		
Antiallergic Agents		
Bepreve*		bepotastine ophthalmic solution (generic)
		Zerviate
	azelastine	
	cromolyn	
	epinastine	
	olopatadine	
Antibacterials		
Besivance*	besifloxacin	
Cipro HC*		ciprofloxacin-hydrocortisone (generic)
Zylet*		tobramycin-loteprednol (generic)
		AzaSite
	ciprofloxacin	Ciloxan*
		Cortisporin-TC
	neomycin, polymyxin B and dexamethasone	Maxitrol*
	ofloxacin	Ocuflox*
	ciprofloxacin and fluocinolone	Otovel*
	tobramycin and dexamethasone	TobraDex*
		TobraDex ST
	tobramycin	Tobrex*
	moxifloxacin	Vigamox*
	gatifloxacin	
	bacitracin	
	bacitracin and polymyxin B	
	ciprofloxacin and dexamethasone	
	erythromycin base	
	gentamicin	
	levofloxacin	
	neomycin, bacitracin and polymyxin B	
	neomycin, bacitracin, polymyxin B and hydrocortisone	
	neomycin, polymyxin B and gramicidin	
	neomycin, polymyxin B and hydrocortisone	
	ofloxacin	
	polymyxin B and trimethoprim	
	sulfacetamide	
	sulfacetamide and prednisolone	
Intranasal Corticosteroids		

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		NO PA REQUIRED	PA REQUIRED
Preferred Brand		Preferred Generic	Non-Preferred Brand or PA Generic
Dymista*		azelastine/fluticasone	
Omnaris			
			QNASL
			QNASL Children
			Ryaltris
			Sinuva
			Xhance
		mometasone nasal spray	
		flunisolide	
		fluticasone	
Gastrointestinal Agents			
5-HT₃ Receptor Antagonists			
none			Anzemet
			Sancuso
			Sustol
		granisetron	
		ondansetron	
		palonosetron	
Antiemetic Antihistamines			
none		meclizine	Antivert*
			Bonjesta
		doxylamine/pyridoxine	Diclegis*
		trimethobenzamide	Tigan*
		dimenhydrinate	
		meclizine	
		prochlorperazine	
Neurokinin-1 Receptor Antagonists			
none			Akynzeo
			Aponvie
			Cinvanti
		aprepitant/fosaprepitant	Emend*
Miscellaneous Antiemetics			
none			Barhemsys
		dronabinol	Marinol*
		scopolamine	Transderm-Scop*
Antiulcer Agents and Acid Suppressants			
none		dexlansoprazole	Dexilant*
			Konvomep
		esomeprazole magnesium	Nexium*
			omeprazole/sodium bicarbonate (generic)
		lansoprazole	Prevacid*
		omeprazole	Prilosec*
		pantoprazole	Protonix*
			Talicia
			Voquenza
			Voquenza Dual
			Voquenza Triple
		lansoprazole/amoxicillin/ clarithromycin	
		rabeprazole	

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Genitourinary Agents		
Genitourinary Smooth Muscle Relaxants: Antimuscarinics		
Oxytrol		
	tolterodine	Detrol*
	tolterodine	Detrol LA*
	fesoterodine	Toviaz*
	solifenacin	Vesicare*
	darifenacin	
	flavoxate	
	oxybutynin	
	tropium	
Genitourinary Smooth Muscle Relaxants: Beta-3 Adrenergic Agonists		
Myrbetriq*	none	mirabegron (generic)
		Gemtesa
Hormones and Synthetic Substitutes		
Androgens		
none		Aveed
		Azmiro
	testosterone cypionate	Depo-Testosterone*
		Jatenzo
		Natesto
	testosterone	Testim*
		Testopel
		Tlando
		Xyosted
	danazol	
	methyltestosterone	
	oxandrolone	
	testosterone enanthate	
Growth Hormone Agents		
Genotropin ^{CC}	none	
Omnitrope ^{CC}		
Skytrofa ^{CC}		
Sogroya ^{CC}		
Zomacton ^{CC}		
		Humatrope
		Ngenla
		Norditropin
		Nutropin
		Serostim
Agents for the Treatment of Hereditary Angioedema		
Hereditary Angioedema (HAE) Agents		
none		Andembry
		Berinert
		Cinryze
		Dawnzera
		Ekterly

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	icatibant	Firazyr*
		Haegarda
		Kalbitor
		Orladeyo
		Ruconest
	icatibant	Sajazir*
		Takhzyro
Immunomodulatory Agents for Multiple Sclerosis (MS)		
Multiple Sclerosis Agents		
Avonex		
Betaseron		
Copaxone*		glatiramer (generic)
Rebif		
Tysabri		
	teriflunomide	Aubagio*
		Bafiertam
		Briumvi
		Extavia
	fingolimod	Gilenya*
		Kesimpta
		Lemtrada
		Mavenclad
		Mayzent
		Ocrevus
		Ocrevus Zunovo
		Plegridy
		Ponvory
		Tascenso ODT
	dimethyl fumarate	Tecfidera*
		Vumerity
		Zeposia (follow TIMs criteria for UC indication)
Pain Management & Autonomic Agents		
Analgesics and Antipyretics, Miscellaneous		
Journavx ^{CC}	none	none
Centrally Acting Skeletal Muscle Relaxants		
none	cyclobenzaprine	Amrix*
		carisoprodol (generic)
	cyclobenzaprine	Fexmid*
	chlorzoxazone	Lorzone*
	methocarbamol	Robaxin*
	metaxalone	
		Soma*
	tizanidine	Zanaflex*
Calcitonin Gene-related Peptide (CGRP) Antagonists		
Aimovig ^{CC}	none	
Ajovy ^{CC}		

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Qulipta ^{cc}		
Ubrelvy ^{cc}		
		Emgality
		Nurtec ODT
		Vyepti
		Zavzpret
Direct-Acting Skeletal Muscle Relaxants		
none	dantrolene	Dantrium*
	dantrolene	Revonto*
		Ryanodex
GABA-derivative Skeletal Muscle Relaxants		
none	baclofen	Fleqsuvy*
	baclofen	Gablofen*
		Lioresal Intrathecal
		Lyvispah
Miscellaneous Skeletal Muscle Relaxants		
none	orphenadrine/aspirin/caffeine	Norgesic Forte*
	orphenadrine	
Opiate Agonists		
none	benzhydrocodone/acetaminophen	Apadaz*
	meperidine	Demerol*
	hydromorphone	Dilaudid*
		Dsuvia
		Duramorph
	fentanyl	Fentora* (discontinued 9/30/2024)
		Infumorph
		methadone (generic)
		Methadose*
	tapentadol	Nucynta*
		Olinvyk
	oxycodone/acetaminophen	Percocet*
		Prolate
	oxycodone	Roxicodone*
		Roxybond
		Seglantis
	remifentanyl	Ultiva*
	alfentanyl	
	codeine	
	codeine/acetaminophen	
	codeine/butalbital/acetaminophen/ caffeine	
	codeine/butalbital/aspirin/caffeine	
	hydrocodone/acetaminophen	
	hydrocodone/ibuprofen	
	ibuprofen/oxycodone	
	levorphanol	
	morphine	
	opium/belladonna	
	oxycodone/aspirin	
	oxymorphone	
	sufentanil	

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		NO PA REQUIRED	PA REQUIRED
Preferred Brand		Preferred Generic	Non-Preferred Brand or PA Generic
	tramadol		
	tramadol/acetaminophen		
Opiate Partial Agonists			
Brixadi ^{CC}			
Sublocade ^{CC}			
			buprenorphine/naloxone film (generic)
			Belbuca
			buprenorphine (generic)
			Butrans*
			Suboxone*
			Zubsolv
	buprenorphine/naloxone tablets ^{CC}		
	butorphanol		
	nalbuphine		
	pentazocine/naloxone		
Selective Serotonin Agonists			
none	frovatriptan		Frova*
	sumatriptan		Imitrex*
	rizatriptan		Maxalt*
	rizatriptan		Maxalt MLT*
	eletriptan		Relpax*
			Reyvow
			Tosymra
			Zembrace
	zolmitriptan		Zomig*
	zolmitriptan		Zomig ZMT*
	almotriptan		
	naratriptan		
	sumatriptan and naproxen		
Allergy and Respiratory Agents			
Asthma and Allergy Monoclonal Antibodies			
Fasenra ^{CC,TIM}	none		Cinqair ^{TIM}
Tezspire ^{CC,TIM}			Exdensur ^{TIM}
Xolair ^{CC,TIM}			Nucala ^{TIM}
			Omlyclo**
Inhaled Antimuscarinics			
Atrovent HFA			
Incruse Ellipta*			umeclidinium (generic)
Spiriva Handihaler*			tiotropium (generic)
Spiriva Respimat			
			Tudorza Pressair
			Yupelri
	ipratropium bromide		
Inhaled Mast-Cell Stabilizers			
none	cromolyn sodium		none
Leukotriene Modifiers			
none	zafirlukast		Accolate*
	montelukast		Singulair*
			zileuton ER (generic)
			Zyflo

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Respiratory Adrenals		
Advair Diskus*		fluticasone/salmeterol (Diskus)
Advair HFA*		fluticasone/salmeterol (HFA)
Arnuity Ellipta*		fluticasone furoate (generic)
Asmanex HFA		
Asmanex Twisthaler		
Breo Ellipta*		fluticasone/vilanterol (generic)
Dulera		
Pulmicort Flexhaler		
QVAR Redihaler		
Symbicort*		budesonide/formoterol (generic)
	fluticasone/salmeterol	AirDuo Respiclick*
		Airsupra
		Alvesco
		Breztri Aerosphere
	budesonide	Pulmicort Respules*
		Trelegy Ellipta
	fluticasone	
Respiratory Beta-Adrenergic Agonists		
Anoro Ellipta*		umeclidinium-vilanterol (generic)
Bevespi		
ProAir Respiclick		
Serevent Diskus		
Stiolto Respimat		
Striverdi Respimat		
Ventolin HFA*	albuterol HFA	
		Combivent Respimat
		Duaklir Pressair
	formoterol	Perforomist*
	levalbuterol HFA	Xopenex HFA*
	levalbuterol inhalation solution	
	albuterol	
	albuterol/ipratropium	
	arformoterol	
	terbutaline	
Respiratory Dual Phosphodiesterase Inhibitors		
		Ohtuvayre
Respiratory Smooth Muscle Relaxants		
none		Theo-24
	aminophylline	
	theophylline	
Skin & Mucous Membrane Agents		
Antibacterials		
none	mupirocin	Centany*
	clindamycin (vaginal only)	Cleocin*
	clindamycin (vaginal only)	Clindesse*
		Neo-Synalar
		Nuessa
		Sulfamylon
	metronidazole	Vandazole*
		Xaciato

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Xepi
	gentamicin	
	neomycin and polymyxin B	
Antifungals		
none	ciclopirox	Ciclodan*
		Ertaczo
		Gynazole-1
		Jublia
	ciclopirox	Loprox*
	luliconazole	Luzu*
	naftifine	Naftin*
		Oravig
	oxiconazole	Oxistat*
	miconazole/zinc/petrolatum	Vusion*
	clotrimazole	
	clotrimazole and betamethasone	
	econazole	
	ketoconazole	
	miconazole	
	nystatin	
	nystatin and triamcinolone	
	sulconazole	
	tavaborole	
	terconazole	
Corticosteroids		
none		
	hydrocortisone	Anusol-HC*
	fluticasone	Beser*
		Bryhali
	clobetasol	Clodan*
	hydrocortisone	Cortenema*
		Cortifoam
	fluocinolone	Derma-Smooth/FS*
	betamethasone dipropionate and propylene glycol	Diprolene*
	triamcinolone	Kenalog*
	halobetasol	Lexette*
	hydrocortisone butyrate	Locoid*
	hydrocortisone butyrate	Locoid lipocream*
	triamcinolone	Oralene*
		Pandel
		ProctoFoam-HC
	fluocinolone	Synalar*
		Texacort
	desoximetasone	Topicort*
	clobetasol	Tovet*
	halobetasol	Ultravate*
	fluocinonide	Vanos*
	alclometasone	
	amcinonide	
	betamethasone dipropionate	
	betamethasone valerate	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	clocortolone	
	halcinonide	
	desonide	
	diflorasone	
	flurandrenolide	
	hydrocortisone	
	mometasone	
	prednicarbate	
Antipruritics and Local Anesthetics		
none	lidocaine topical patch	Lidoderm*
	doxepin	Prudoxin*
	doxepin	Zonalon*
		ZTLido
	lidocaine	
	lidocaine and prilocaine	
Antivirals		
none	penciclovir	Denavir*
		Xerese
		Ycanth
		Zovirax (cream)
	acyclovir	Zovirax (ointment)*
Cell Stimulants and Proliferants		
none	none	none
Immunomodulatory Agents		
Adbry ^{CC,TIM}		
Dupixent ^{CC,TIM}		
Ebglyss ^{CC,TIM}		
		pimecrolimus (generic)
Nemluvio ^{CC,TIM}		
Rhapsido ^{CC,TIM}		
		Bimzelx ^{TIM}
		Hyftor
		Ilumya ^{TIM}
		Siliq ^{TIM}
		Skyrizi ^{TIM}
		Spevigo ^{TIM}
		Tremfya ^{TIM}
	tacrolimus	
Janus Kinase Inhibitors		
none		Cibinqo ^{TIM}
		Opzelura
		Sotyktu ^{TIM}
Keratolytic Agents		
none	podofilox	Condylox*
		Duobrii
		Podocon-25
		Veregen
	acitretin	
	tazarotene	
Miscellaneous Anti-inflammatory Agents		
none	none	none
Miscellaneous Local Anti-infectives		

*Denotes a generic available in at least one dosage form or strength

Effective 10/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED		PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
none	silver sulfadiazine	Silvadene*
	silver sulfadiazine	SSD*
	silver nitrate	
Miscellaneous Skin and Mucous Membrane Agents		
none		Filsuvez
	calcitriol	
Phosphodiesterase-4 Inhibitors		
Eucrisa ^{CC}		
		Adquey**
		Zoryve
Scabicides and Pediculicides		
none		Crotan
	spinosad	Natroba*
	crotamiton	Pruradik*
	ivermectin	
	malathion	
	permethrin	
Women's Health		
Estrogens/ Treatments for Menopausal Symptoms		
Premarin (cream and tablets only)		conjugated estrogens tablets (generic)
Prempro		
	estradiol and norethindrone	Activella*
		Angeliq
		Bijuva
	estradiol	Climara*
		Climara Pro
		Combipatch
	estradiol valerate	Delestrogen*
		Depo-Estradiol
	estradiol	Divigel*
		Duavee
		Elestrin
	estradiol	Estrace*
		Estring
		Evamist
		Femring
	ethinyl estradiol and norethindrone	Jinteli*
		Menest
		Menostar
	estradiol and norethindrone	Mimvey*
		Prefest
		Premarin (injection)
		Premphase
	estradiol	Vagifem*
		Veozah
	estradiol	Vivelle-Dot*
Prenatal Vitamins		
Concept DHA*	prenatal vitamins, iron, folic acid, omega-3 fatty acids	
Concept OB*	prenatal vitamins, iron, folic acid	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026

NO PA REQUIRED		NO PA REQUIRED	PA REQUIRED
Preferred Brand		Preferred Generic	Non-Preferred Brand or PA Generic
Nestabs			
Nestabs DHA			
Thrivite Rx			
Tricare			
Vinate II			
Vitafof FE+ softgel			
Vitafof Prenatal w/iron Gummies			
Vitafof-OB			
Vitafof-OB+DHA			
Vitafof-One softgel			
Vitafof Ultra softgel			
			Citranatal 90 DHA
			Citranatal Assure
			Enbrace HR
			Nestabs One
	prenatal vitamins, iron, folic acid		OB Complete*
			OB Complete One
			OB Complete Petite
			OB-Complete Premier
			OB Complete with DHA
			Prenate
			Prenate AM
			Prenate DHA
			Prenate Elite
			Prenate Enhance
			Prenate Essential
			Prenate Mini
			Prenate Pixie
			Prenate Restore
			Prenate Star
			Primacare
			Provida OB
			Select-OB
			Select-OB+DHA
			Tristart DHA
			Vinate DHA RF
			VP-CH Plus
	prenatal vitamins, calcium, iron, folate		
	prenatal vitamins, calcium, iron, folic acid		
	prenatal vitamins, iron, folate		
	prenatal vitamins, iron, folic acid, DHA		
	prenatal vitamins, iron, folic acid, DHA, omega-3		

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 10/01/2026